Kangchen Pharmaceutical (01681) disclosed through an official filing that it repurchased 50,000 of its own shares on July 16, 2025. The transaction amounted to HK$585,000 in total expenditure. This strategic move reflects the company's ongoing capital management initiative aimed at enhancing shareholder value through targeted equity acquisitions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.